VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Scagliotti on Targeted Therapies and Chemotherapy

Giorgio V. Scagliotti, MD, PhD
Published: Friday, Aug 31, 2012

Giorgio V. Scagliotti, MD, PhD, head of the Thoracic Oncology Unit, Department of Clinical and Biological Sciences, University of Turin, San Luigi Hospital, Orbassano, Italy, discusses the administration of targeted therapies and chemotherapy for patients with non-small cell lung cancer (NSCLC).

Scagliotti believes that chemotherapy and targeted therapies can be used together, when given sequentially. As an example, patents that develop an acquired mutation in T790M after receiving an EGFR targeted therapy may be more sensitive to chemotherapy. Additionally, trials have shown that patients with ALK translocations demonstrate lower TS RNA levels, denoting sensitivity to pemetrexed.

Overall, targeted therapies and chemotherapy should not be used concomitantly, Scagliotti believes. But in the near future, for a molecularly defined patient population, targeted therapies could be combined in a sequential fashion with cytotoxic chemotherapies for patients with NSCLC.

Giorgio V. Scagliotti, MD, PhD, head of the Thoracic Oncology Unit, Department of Clinical and Biological Sciences, University of Turin, San Luigi Hospital, Orbassano, Italy, discusses the administration of targeted therapies and chemotherapy for patients with non-small cell lung cancer (NSCLC).

Scagliotti believes that chemotherapy and targeted therapies can be used together, when given sequentially. As an example, patents that develop an acquired mutation in T790M after receiving an EGFR targeted therapy may be more sensitive to chemotherapy. Additionally, trials have shown that patients with ALK translocations demonstrate lower TS RNA levels, denoting sensitivity to pemetrexed.

Overall, targeted therapies and chemotherapy should not be used concomitantly, Scagliotti believes. But in the near future, for a molecularly defined patient population, targeted therapies could be combined in a sequential fashion with cytotoxic chemotherapies for patients with NSCLC.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x